Are there differences in acute phase inflammation markers regarding the type of heart failure?

This study aimed to determine if there are differences in inflammatory markers in the acute phase between systolic heart failure and heart failure with preserved systolic function. One hundred and thirty-one patients with acute heart failure were recruited consecutively. At admission, plasma fibrinogen, C-reactive protein, sialic acid, von Willebrand factor, vascular endothelial growth factor, interleukin-6 and NTproBNP were all evaluated. If the ejection fraction was 45% or over patients were included in the HF-PSF group; the remaining patients were included in the SHF group. The HF-PSF patients were older (72±10 vs 63±12 years, P<0.001), presented a higher rate of atrial fibrillation (56.1 vs 21.3%, P<0.001), and had a lower rate of hemoglobin (12.2±2 vs 13.3±2.1 g/dL, P<0.01). No significant differences were observed in the inflammation markers analyzed among SHF and HF-PSF groups. In the acute phase of heart failure there is a marked elevation of inflammatory markers but there are no differences in the inflammatory markers analyzed between the two different types of heart failure.

[1]  T. Kitazono,et al.  Predictive role of C reactive protein in stroke recurrence after cardioembolic stroke: the Fukuoka Stroke Registry , 2013, BMJ Open.

[2]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[3]  I. Kubota,et al.  Combination of conventional biomarkers for risk stratification in chronic heart failure. , 2009, Journal of cardiology.

[4]  D. Kaye,et al.  Heart failure with normal left ventricular ejection fraction. , 2009, Journal of the American College of Cardiology.

[5]  M. Cheitlin.  Inflammatory pathways in patients with heart failure and preserved ejection fraction , 2009 .

[6]  P. Villa,et al.  Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. , 2008, International journal of cardiology.

[7]  L. Martínez-Dolz,et al.  Inflammatory markers in stable heart failure and their relationship with functional class. , 2008, International journal of cardiology.

[8]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[9]  Y. Arbel,et al.  Predictive value of high sensitivity CRP in patients with diastolic heart failure. , 2008, International journal of cardiology.

[10]  M. Valdés,et al.  Red de investigación clínica y básica en insuficiencia cardiaca (REDINSCOR). Redes temáticas de investigación cooperativa del Instituto de Salud Carlos III , 2008 .

[11]  P. Villa,et al.  Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure. , 2008, Thrombosis research.

[12]  J. Brugada,et al.  [Clinical and Preclinical Heart Failure Research Network (REDINSCOR). Instituto de Salud Carlos III Cooperative Special Topic Research Networks]. , 2008, Revista espanola de cardiologia.

[13]  C. Hengstenberg,et al.  Head-to-head comparison of BNP and IL-6 as markers of clinical and experimental heart failure: Superiority of BNP. , 2007, Cytokine.

[14]  Kanu Chatterjee,et al.  Systolic and diastolic heart failure: differences and similarities. , 2007, Journal of cardiac failure.

[15]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[16]  W. Markiewicz,et al.  Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. , 2006, Journal of the American College of Cardiology.

[17]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[18]  Y. Kihara,et al.  B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. , 2006, Journal of the American College of Cardiology.

[19]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[20]  G. Torre-Amione.  Immune activation in chronic heart failure. , 2005, The American journal of cardiology.

[21]  M. Rizzo,et al.  Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study. , 2005, Italian heart journal : official journal of the Italian Federation of Cardiology.

[22]  P. Libby,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. , 2004, Circulation.

[23]  George A Mensah,et al.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. , 2004, Circulation.

[24]  S. Graf,et al.  Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  G. Lip,et al.  Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new ‘vascular triad’ , 2004, Annals of medicine.

[26]  G. Lip,et al.  Assessment of endothelial damage and dysfunction: observations in relation to heart failure. , 2003, QJM : monthly journal of the Association of Physicians.

[27]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[28]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[29]  P. Blasco,et al.  Valor pronóstico del fibrinógeno en pacientes ingresados con sospecha de angina inestable o infarto de miocardio sin onda Q , 2002 .

[30]  J. Rueda Soriano,et al.  [Prognostic value of fibrinogen in patients admitted with suspected unstable angina and non-q-wave myocardial infarction]. , 2002, Revista espanola de cardiologia.

[31]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[32]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[33]  R. Vasan,et al.  Defining diastolic heart failure: a call for standardized diagnostic criteria. , 2000, Circulation.

[34]  G. Sanz,et al.  Serum interleukin-6 in congestive heart failure secondary to idiopathic dilated cardiomyopathy. , 1998, The American journal of cardiology.

[35]  J. Goldman,et al.  Increased ventricular sialylation in patients with heart failure secondary to ischemic heart disease , 1997, Clinical cardiology.

[36]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[37]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[38]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.